Stockholm Longevity x AI Hackathon, Epicenter, Sep 11–13, 2026

Build longevity AI on cited biomedical evidence.

Amass is a tooling partner of the hackathon. Every team gets $500 in Amass API credits. It is one REST API across six cross-linked *Cores: biomedical literature, clinical trials, drugs, genes, FDA + EMA regulatory, and patents.

The organizers’ advice is “build for evidence, not theatre”. That is what this engine returns: full records, typed schemas, every answer cited to source. Find below how to claim your team’s credits, a gallery of apps to fork, and a copy-paste API recipe for each track.

Claim your team’s $500 →Jump to your track ↓

Sign up with your hackathon email, then redeem your team’s promo code. We share the code at the Amass talk Friday 16:45, or message Henrik or Jörn any time. Valid until 20 September 2026. Questions? hello@amass.tech.

your agent / amass api

you ▸Is metformin a credible geroprotector, and what is it actually approved for?

trialcoreMILESAMTC_5qsK…
NCT02432287 · Phase 4 · Albert Einstein · N=16 · completed, results posted
trialcoreANTHEMAMTC_ScJv…
NCT04264897 · Phase 3 · N=166 · completed 2025, results posted
regulatorycoreRiomet (metformin)AMRC_Pytg…
FDA label · indication: type 2 diabetes · no ageing indication on record
biomedcoreDNA Methylation Clocks in AgingAMBC_IJRR…
Molecular Cell 2018 · 670 citations · JuFo 3, the endpoint layer

✓

Partly. Two completed RCTs (MILES, ANTHEM) tested metformin against ageing biology and posted results, but every FDA and EMA authorization is for type 2 diabetes. A longevity claim has to stand on the primary evidence, cited.

trial → trial → label → literature: four calls, every hop cited.

The offer

Claim your team’s $500 in API credits

Sign up with the same email you registered for the hackathon with, then redeem the promo code we hand out at the event: one code per team, worth $500.

Sign up with your hackathon email

Create an account at platform.amass.tech using the email you signed up for the hackathon with.

Redeem your team’s promo code

We give out the code at the Amass talk (Friday 16:45), or ask Henrik or Jörn directly. Redeem it once per team for $500, valid until 20 September 2026; check the balance via GET /v1/credits/api-credits.

Create a key & build

Open API Keys, click Create API Key (starts with amass_, shown once), and make your first call.

Need the code?

Get it at the Amass talk on Friday, or from Henrik or Jörn on the event WhatsApp, Discord, LinkedIn, or hello@amass.tech.

What $500 buys

≈ 10,000 searches or 50,000 record fetches. Search is $0.05 per 20 results; get-by-id and lookup are $0.01 each. Plenty of headroom for a team’s weekend.

Get started

From key to first response in a minute

Everything lives at platform.amass.tech. One base URL, one auth header, JSON back, and an assistant that writes the calls with you.

Start with this

The Amass build assistant

This is a chat grounded in the Amass documentation, built to help you write against the API. Describe what you are trying to do, such as finding every completed geroprotector trial with posted results and the papers behind them. It answers with the endpoint, the filters, and the field names, so you are not guessing at parameter names from a schema you have not read yet.

Open the assistant →

bash

# base: https://api.amass.tech/api/v1
# auth: Authorization: Bearer amass_YOUR_KEY  (every request)
curl "https://api.amass.tech/api/v1/cores/trialcore/records\
?query=metformin+aging+longevity&limit=5" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK

{
  "data": [
    {
      "amassId": "AMTC_…",
      "briefTitle": "Metformin in Longevity Study (MILES).",
      "phase": "PHASE4",
      "overallStatus": "COMPLETED",
      "sponsorName": "Albert Einstein College of Medicine",
      "enrollment": 16
    }
  ]
}

Platform & keys

Open

API reference

Interactive docs for all six *Cores, every param and field.

Open

Quickstart

Your first cited response in under five minutes.

Open

LLM quick reference

Self-contained, paste into your agent’s system prompt.

Open

Starter agent · Python

A runnable natural-language agent with the API loop built in.

Open

Starter agent · TypeScript

The same agentic loop in TypeScript, ready for a Node or web app.

Open

OpenAPI spec

Machine-readable: code-gen, Postman, type inference.

Open

Agents or apps

Not just agents, build apps too

The tracks below are agent recipes. But the same REST API, same key, same cited records, just as readily powers a small, interactive app: a geroscience trial atlas, a longevity-claim checker, a target-to-approval explorer. All 19 in the gallery were built with Lovable (also in the hackathon tooling stack). Fork one, point it at your key, and remix.

Browse the app gallery →No-code recipes

platform.amass.tech/app-gallery

Research

From Gene to Approval

One gene → every drug, trial, and FDA/EMA approval behind it.

Research

Graveyard & Garden

25 years of late-stage trials, halted or still alive.

Research

Clinical Trial Atlas

Where a drug is tested, and which regions are enrolling.

Research

Indication Timeline

A drug across its Phase-3 indications and approvals.

Regulatory

Transatlantic Divergence Desk

FDA versus EMA outcomes, side by side.

Clinical

Pipeline Monitor

A weekly digest of new Phase 2/3 trials by sponsor.

Nineteen starter apps across research, regulatory, and clinical. Fork, remix, and ship your own on your team’s $500 in credits.

The data

Six cross-linked *Cores

Same auth, same error format, same rate limits across all of them. Every record cross-links to the others, so a paper, trial, drug, gene, and approval all resolve to the same entity.

BioMedCore

43M+

/cores/biomedcore/records

Peer-reviewed biomedical literature from PubMed and PubMed Central. Every record includes MeSH terms and IDs, publication types (RCT, meta-analysis, systematic review), JuFo 0–3 journal quality tier, citation count, DOI, PMID, and PMCID. Optional: full text for PMC articles, ORCID-disambiguated authors with ROR-mapped affiliations, and links to the trials each paper describes in TrialCore. Conference abstracts sit in the same index and carry the Amass-assigned value Conference in publicationTypes.

TrialCore

1.2M+

/cores/trialcore/records

Clinical trial records from ClinicalTrials.gov and international registries. Includes protocol data, eligibility criteria, primary and secondary endpoints, sponsor details, arm groups, recruitment status, NCT ID, and the full lifecycle: start, completion, results posting, and why stopped. Outcome measurements are available as structured values per arm. Records link back to the publications that describe them in BioMedCore.

DrugCore

22K+

/cores/drugcore/records

ChEMBL-derived drugs and molecules, harmonized. Names, trade names, and synonyms; chemical structures with InChIKey and SMILES; modality classification; and highest clinical stage from preclinical through approval. Each drug cross-links to the trials, papers, and regulatory authorizations it appears in.

RegulatoryCore

7K+

/cores/regulatorycore/records

FDA and EMA regulatory data on one unified schema. FDA application records, drug labels, review documents, and approval letters; EMA EPARs, assessment reports, and SmPCs. Each record carries a unified authorization status, designations (Breakthrough Therapy, PRIME, Accelerated Approval), and orphan status, and cross-links to the drug it covers in DrugCore.

GeneCore

43K+

/cores/genecore/records

43,000+ harmonized human gene records from HGNC, NCBI, UniProt, and Ensembl. Druggability and tractability assessments, target safety data, genetic constraint via gnomAD v4.0 (pLI, LOEUF), and cellular essentiality from CRISPR dependency screens. Each gene cross-links to the drugs that target it in DrugCore; follow those links to their trials, papers and approvals.

PatentCore

170M+

/cores/patentcore/records

Patent publications with English-preferred full text (title, abstract, claims, and description) plus bibliographic metadata (publication and application numbers, jurisdiction, kind code, family id), CPC/IPC classifications, inventors and assignees, four separate dates, and citation lineage. Search returns one publication per family, the most relevant member, and every record cross-links to the drugs it mentions in DrugCore and the papers it cites in BioMedCore.

Tracks

An API recipe for every track

Inspiration, not coverage. Each command below was run against the live API and the responses are real (trimmed for width). Jump to your track:

1 · Longevity Biology × AI 2 · AI Infrastructure — Nebius 3 · Communication, Trust & Policy 4 · Healthspan & Clinical Translation 5 · Open / Wildcard

Track

1 · Longevity Biology × AI

Ageing clocks and biomarker inference, target triage for the biology of ageing, AI-supported drug repurposing, in-silico trials: defensible applications of AI to how we age.

BioMedCoreGeneCoreDrugCore

Ground an ageing-clock build in the actual methodology, ranked by journal quality and citations, cited to source.

bash

curl "https://api.amass.tech/api/v1/cores/biomedcore/records\
?query=epigenetic+clock+DNA+methylation+biological+age\
&minJournalQualityJufo=2&limit=4" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · 4 records, JuFo ≥ 2

TITLE                                                  JOURNAL           YR   CITED
DNA Methylation Clocks in Aging: Categories, Causes…   Molecular Cell    2018   670
Tracking the Epigenetic Clock Across the Human Life…   J Gerontol A      2019   139
Epigenetic Aging: More Than Just a Clock When It…      Cancer Research   2020   129
Retro-age: A unique epigenetic biomarker of aging…     Aging Cell        2024    26

Triage an ageing target in one call: SIRT1 comes back with clinical-precedent tractability, genetic constraint, and curated safety signals, each with the numbers to defend the pick.

bash

curl "https://api.amass.tech/api/v1/cores/genecore/records\
?query=SIRT1&limit=1" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · GeneCore SIRT1

symbol            SIRT1
location          10q21.3          LOEUF  0.527   pLI  0.90
targetClass       Epigenetic regulator › Eraser › HDAC class III
tractability      small molecule: Advanced Clinical
                  Structure with Ligand · High-Quality Ligand · Druggable Family
safetyLiabilities
  • regulation of catalytic activity      ToxCast

Also try

For the repurposing half: DrugCore resolves “rapamycin mTOR inhibitor” to harmonized candidates with clinical stage (ridaforolimus at Approval, vistusertib and sapanisertib at Phase 2). Cross-link each hit into TrialCore for the trials that ran it and BioMedCore for the papers behind it.

Track

2 · AI Infrastructure — Nebius

A performant, scalable longevity-compute solution on the Nebius stack. Whatever you serve needs a grounded data layer behind it. Amass is one REST API with typed schemas and predictable limits, built to sit inside a pipeline.

All six *CoresOpenAPI

Hydrate a feature store or vector index with harmonized records. Same query, same result, safe to cache hard.

bash

curl "https://api.amass.tech/api/v1/cores/drugcore/records\
?query=rapamycin+mTOR+inhibitor\
&drugType=SMALL_MOLECULE&limit=5" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · cache-friendly

NAME            CHEMBL          STAGE
Ridaforolimus   CHEMBL2103839   APPROVAL
RG-7603         CHEMBL2331680   PHASE1
Vistusertib     CHEMBL2336325   PHASE2
Palomid-529     CHEMBL2141712   PHASE1
AZD-8055        CHEMBL1801204   PHASE1/PHASE2

Also try

The plumbing that matters at scale: 60 requests / 60s with X-RateLimit-Remaining and X-Amass-Credit-Cost on every response, a flat { data } envelope, batch /lookup endpoints for external IDs, and a machine-readable OpenAPI spec at api.amass.tech/api/doc/openapi.json for code-gen and typed clients.

Track

3 · Communication, Trust & Policy

Products, tools, or campaigns that make longevity science understandable and credible: misinformation checkers, claim graders, responsible-adoption workflows.

RegulatoryCoreBioMedCoreTrialCore

What is metformin actually approved for? Sweep the unified FDA + EMA record: every authorization is type 2 diabetes, none is longevity. That gap is what a claim checker tests headlines against.

bash

curl "https://api.amass.tech/api/v1/cores/regulatorycore/records\
?query=metformin&limit=4" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · FDA + EMA, unified

NAME         AGENCY   STATUS                ACTIVE SUBSTANCE · INDICATION
Riomet       FDA      WITHDRAWN_VOLUNTARY   Metformin HCl · type 2 diabetes
Jentadueto   EMA      ACTIVE                Linagliptin;Metformin · type 2 diabetes
Kazano       FDA      ACTIVE                Alogliptin + metformin · type 2 diabetes
Synjardy     EMA      ACTIVE                Empagliflozin;Metformin · type 2 diabetes
# no metformin authorization carries an ageing or longevity indication

Also try

For the claim grader: BioMedCore carries isRetracted, journalQualityJufo (0–3), and citation counts on every record, enough to separate “one small study” from settled literature. TrialCore's hasResults and whyStopped distinguish tested from merely registered.

Track

4 · Healthspan & Clinical Translation

Clinician-facing tools, preventive-health workflows, and credible pathways from data or research to real-world healthspan applications.

TrialCoreRegulatoryCore

The human evidence for metformin as a geroprotector, in one call: two completed RCTs with posted results, and the next one still recruiting.

bash

curl "https://api.amass.tech/api/v1/cores/trialcore/records\
?query=metformin+aging+longevity&limit=4" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · geroscience RCTs

TRIAL         REGISTRY ID   PHASE    STATUS       N    RESULTS
MILES         NCT02432287   PHASE4   COMPLETED    16   posted
ANTHEM        NCT04264897   PHASE3   COMPLETED   166   posted
AGE-M         NCT06459310   PHASE2   RECRUITING  130   —
(Padova)      NCT01765946   PHASE4   COMPLETED    38   —

Healthspan is more than drugs. TrialCore covers the WHO ICTRP registries too, so exercise and nutrition interventions from Thailand to Mexico are one query away.

bash

curl "https://api.amass.tech/api/v1/cores/trialcore/records\
?query=sarcopenia+older+adults\
&overallStatus=COMPLETED&hasResults=true&limit=4" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · beyond ClinicalTrials.gov

REGISTRY   ID                INTERVENTION                          N    COUNTRY
tctr       TCTR20230703001   resistance exercise + whey protein    25   MY
isrctn     ISRCTN48485253    tai chi vs resistance exercise       120   MX
isrctn     ISRCTN17269170    social-media exercise programme       35   CN
tctr       TCTR20231005004   virtual-reality exercise              58   TH

Also try

To keep a clinician tool inside the label: RegulatoryCore parses FDA labels and EMA SmPCs into addressable sections, so a workflow can quote the exact contraindication passage, id and all, instead of a summary.

Track

5 · Open / Wildcard

Propose your own challenge at the frontier of AI and longevity biotech. By definition you already know the problem; the whole engine is open, and the strongest entries usually chain *Cores together.

All six *CoresCross-Core links

Cross-Core links let one entity resolve across all six *Cores, every hop cited to source.

bash

curl "https://api.amass.tech/api/v1/cores/genecore/records\
?query=SIRT1&include=referencesDrugCore&limit=1" \
  -H "Authorization: Bearer amass_YOUR_KEY"

response · 200 OK · one gene → the whole thread

SIRT1  →  referencesDrugCore: the drugs that target it
             │
             ├─ each drug → referencesTrialCore       (the trials that ran it)
             ├─ each drug → referencesBiomedCore      (the papers behind it)
             └─ each drug → referencesRegulatoryCore  (FDA / EMA labels)

gene → drug → trial → paper → approval, in one thread. all cited.

Playbook

Nine ways to get further, faster

40% of the judging rubric is impact plus evidence and responsible use, and a demo that cites its sources scores on both. These patterns separate a build that lands from one that fights its own plumbing.

Build an agent, not a script.

Let the model call the API in a loop: search broadly, filter, drill into a record, repeat. Our open-source starter agents (Python and TypeScript) ship exactly this loop; fork one and go.

Ground every claim in a record.

Each result carries a stable Amass id and resolves back to its source: the PMID, NCT number, or patent record behind it.

Cross-Core is your edge.

A gene resolves to the drugs that target it, the trials that ran them, the papers behind them, and the FDA/EMA labels that cover them. Follow the links, one call at a time. Treat an empty reference array as “none recorded,” not “no evidence.”

Query, do not scrape.

PubMed, ClinicalTrials.gov, WHO ICTRP, ChEMBL, HGNC, UniProt, FDA & EMA are already normalised and cross-linked. Spend your weekend on the idea, not the ETL.

Narrow with filters.

journalQualityJufo, phase, maxConstraintLoeuf, tractability, agency… tighter queries mean higher signal and fewer credits burned. Skip include=fulltext unless you need it.

Be nice to the rate limit.

60 requests / 60s, keyed by user + org. On a 429, read Retry-After and back off exponentially. Every response carries X-RateLimit-Remaining and X-Amass-Credit-Cost.

Read the data envelope.

Every response is wrapped in { "data": … }; errors come back in a different shape under "error". Read results from data, and check for error before you parse. A batch lookup can even fail item-by-item.

Convert external IDs first.

Get-by-id endpoints take Amass IDs only (AMBC_, AMTC_, AMDC_, AMRC_, AMGC_). Holding PMIDs, DOIs, NCTs, ChEMBL, or gene IDs? Batch them through the /lookup endpoints, then fetch.

Cache, and mind pagination.

Same query, same result. Memoise locally so a weekend of iterating does not re-spend credits. And there is no pagination: 300 results max per search, so narrow with filters instead of trying to page.

Prototype in Claude

Sketch your agent in Claude before you write app code.

Connect the Amass MCP in Claude.ai, Claude Code, Cursor, ChatGPT, or Codex and query all six *Cores in natural language. Explore the data, find the filters that work, then drop the same queries into the REST API in your build.

In Claude Code, install the Amass SKILL.md and let the model wire up your data layer for you, a quick path from “what data is even in here?” to a working prototype.

Connect the MCPStarter agent:Python TypeScript

Go further

More ways to put the credits to work

Not a coder on your team, or just want to move faster? Pick a lane.

Fork an app from the gallery

Nineteen starter apps (trial atlas, indication timeline, gene-to-approval) built on the same API. Fork one and remix it with your key.

Browse the gallery

No-code builds

Paste your key into Lovable, Streamlit, or an n8n HTTP node and ship a filterable trial tracker or literature app.

See examples

Claude Code + SKILL.md

Install the Amass skill and let Claude Code build your Amass data layer, then iterate on the science instead of the SDK.

Get the skill

Demo it live in Claude

With the MCP connected, your agent’s answers come back cited in the chat, a clean, judge-friendly demo with zero deploy.

How it works

Chain the *Cores

Strong entries fan out: gene → drug → trial → paper → label. Follow the reference fields and cite every hop.

See the wildcard track

Share on Discord

Show what you are building with life-science AI builders, and tag the Amass team for a boost.

Join now

On the ground

Meet the Amass mentors on-site

Henrik Jensen (co-founder & CEO) and Jörn Petersen (AI & data engineer) are your in-person mentors. Catch the Amass talk Friday 16:45, then find them in the Saturday mentor rotations for the promo code, API help, or to talk through your build. Off-site they answer on the event WhatsApp, Discord, LinkedIn, and email. Meet the full Amass team →

Henrik's LinkedIn Jörn's LinkedIn Email

Go build for longer, healthier lives

Redeem your team’s $500 in credits, wire up a *Core, and let an agent do the reading. Build for evidence, not theatre.

Claim your team’s $500 →API reference Connect the MCP

One promo code per team, from the Friday talk or from Henrik and Jörn. Valid until 20 September 2026. Questions? hello@amass.tech

Data: No training on your data
Hosting: EU-hosted, enterprise
Isolation: Tenant-isolated by architecture
Certification: ISO 27001, SOC 2, NIS2: in motion